Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris

PHASE1CompletedINTERVENTIONAL
Enrollment

601

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Acne Vulgaris
Interventions
DRUG

Adapalene

0.1% Topical Gel

DRUG

Differin®

0.1% Topical Gel

DRUG

Placebo

Gel Base

Trial Locations (22)

14609

Helendale Dermatology & Medical Spa, LLC, Rochester

14623

Dermatology Associates of Rochester, PC, Rochester

15206

Novum Pharmaceutical Research Services, Pittsburgh

21201

SNBL Clinical Pharmacology Center, Inc., Baltimore

27262

Office of Zoe Diana Draelos, MD, High Point

30263

MedaPhase, Inc., Newnan

33024

University Clinical Research, Inc., Pembroke Pines

37920

Knoxville Dermatology, PC, Knoxville

45219

University Dermatology Consultants, Inc., Cincinnati

48038

Michigan Center for Research Corportation, Clinton Township

53209

Aurora Advanced Healthcare, Inc., Milwaukee

72205

Dermatology Research of Arkansas, Little Rock

75701

Dermatology Associates of Tyler, Tyler

76011

Arlington Center for Dermatology, Arlington

77030

Center for Clinical Studies, Houston

77058

Center for Clinical Studies, Houston

80209

Cherry Creek Research, Inc., Denver

87106

Academic Dermatology Associates, Albuquerque

89119

Office of Atoya Breona Adams, MD, Las Vegas

90045

Dermatology Research Associates, Los Angeles

Unknown

Dermatology and Skin Surgery Centre, Belize City

FXM Research International, Belize City

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT01182636 - Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris | Biotech Hunter | Biotech Hunter